LNTH240719C92500
- 0.92
- 0.000.00%
Lantheus Newsroom
Is Lantheus Holdings (NASDAQ:LNTH) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Truist Financial Maintains Lantheus(LNTH.US) With Buy Rating
Truist Financial analyst Richard Newitter maintains $Lantheus(LNTH.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 58.1% and a total average return of 15.8% over t
JonesTrading Maintains Lantheus(LNTH.US) With Buy Rating, Maintains Target Price $128
JonesTrading analyst Justin Walsh maintains $Lantheus(LNTH.US)$ with a buy rating, and maintains the target price at $128.According to TipRanks data, the analyst has a success rate of 32.9% and a tota
Unusual Options Activity: CVS, DKNG and Others Attract Market Bets, CVS V/OI Ratio Reaches 137.5
EST Jun 27th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Lantheus Holdings Acquires Global Rights to Life Molecular Imaging's RM2
Lantheus Holdings (LNTH) said Thursday that it is acquiring global rights of Life Molecular Imaging's RM2, targeting the gastrin-releasing peptide receptor for prostate and breast cancers. The company
Lantheus Expands Cancer Pipeline With $35M Acquisition of RM2 Rights
Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcome
Express News | Lantheus Holdings Inc - to Begin Phase 1/2a Study With (177)Lu-Dota-Rm2 in 2025
Express News | Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting Grpr for Prostate and Breast Cancers
B. Riley Raises Price Target on Lantheus Holdings to $105 From $99, Maintains Buy Rating
Lantheus Holdings (LNTH) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $96 to $128.
Radiopharm Theranostics Secures $70m in Funding With Major Stake From Lantheus Holdings
Lantheus Makes $12 Million Investment in Radiopharm
Lantheus (LNTH) has agreed to make an initial strategic equity investment of 7.5 million Australian dollars ($5 million) in the company, Radiopharm said on Friday. The US-based pharmaceutical company
Radiopharm Receives Strategic Investment for up to A$18 Million
Radiopharm Theranostics Limited (ASX:RAD) has entered into strategic agreements with Lantheus Holdings, Inc. (LNTH.NASDAQ).
Express News | Radiopharm Theranostics - Lantheus Subscribed for up to a$7.5 Mln at a$0.05 per Share
Express News | Radiopharm Theranostics - Net Proceeds of Lantheus' Investment Will Be Used for Drug Manufacturing, Clinical Trials, Among Others
Are Robust Financials Driving The Recent Rally In Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Stock?
Lantheus Holdings (LNTH) Stock Sinks As Market Gains: What You Should Know
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
Lantheus(LNTH.US) Officer Sells US$27,201.57 in Common Stock
$Lantheus(LNTH.US)$ Officer Sabens Andrea sold 341 shares of common stock on Jun 13, 2024 at an average price of $79.77 for a total value of $27,201.57.Source: Announcement What is statement of change
Lantheus Holdings (NASDAQ:LNTH) Shareholders Have Earned a 48% CAGR Over the Last Three Years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can make much more than 100% if the company does well. For example, the Lantheus Holdi
Lantheus Holdings (LNTH) Stock Drops Despite Market Gains: Important Facts to Note